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Chronic use of proton-pump inhibitors (PPIs) is common in kidney transplant recipients
(KTRs). However, concerns are emerging about the potential long-term complications of
PPI therapy. We aimed to investigate whether PPI use is associated with excess mortality
risk in KTRs.
Methods and findings
We investigated the association of PPI use with mortality risk using multivariable Cox pro-
portional hazard regression analyses in a single-center prospective cohort of 703 stable
outpatient KTRs, who visited the outpatient clinic of the University Medical Center Gro-
ningen (UMCG) between November 2008 and March 2011 (ClinicalTrials.gov Identifier
NCT02811835). Independent replication of the results was performed in a prospective
cohort of 656 KTRs from the University Hospitals Leuven (NCT01331668). Mean age was
53 ± 13 years, 57% were male, and 56.6% used PPIs. During median follow-up of 8.2 (4.7–
9.0) years, 194 KTRs died. In univariable Cox regression analyses, PPI use was associated
with an almost 2 times higher mortality risk (hazard ratio [HR] 1.86, 95% CI 1.38–2.52, P <
0.001) compared with no use. After adjustment for potential confounders, PPI use remained
independently associated with mortality (HR 1.68, 95% CI 1.21–2.33, P = 0.002). Moreover,
the HR for mortality risk in KTRs taking a high PPI dose (>20 mg omeprazole equivalents/
day) compared with patients taking no PPIs (HR 2.14, 95% CI 1.48–3.09, P < 0.001) was
higher than in KTRs taking a low PPI dose (HR 1.72, 95% CI 1.23–2.39, P = 0.001). These
findings were replicated in the Leuven Renal Transplant Cohort. The main limitation of this
study is its observational design, which precludes conclusions about causation.
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Conclusions
We demonstrated that PPI use is associated with an increased mortality risk in KTRs, inde-
pendent of potential confounders. Moreover, our data suggest that this risk is highest
among KTRs taking high PPI dosages. Because of the observational nature of our data, our
results require further corroboration before it can be recommended to avoid the long-term
use of PPIs in KTRs.
Trial registration
ClinicalTrials.gov Identifier: NCT02811835, NCT01331668.
Author summary
Why was this study done?
• Proton-pump inhibitors (PPIs) are commonly prescribed to prevent gastrointestinal
side effects of immunosuppressive medication after kidney transplantation, and there is
little incentive to discontinue use of PPIs in the long term.
• Several observational studies among individuals from the general population and
among patients on hemodialysis have found that PPI use is associated with a higher
mortality risk.
• Long-term mortality rates in kidney transplant recipients (KTRs) are high. Therefore,
we aimed to investigate whether PPI use is associated with increased mortality risk in
KTRs.
What did the researchers do and find?
• We performed a post hoc analysis using data from the TransplantLines Food and Nutri-
tion Biobank and Cohort Study, a prospective cohort study in 703 KTRs, with baseline
assessments performed between November 2008 and March 2011. Follow-up was per-
formed for a median of 8.2 years.
• We found that PPI users had an almost 2-fold increased mortality risk compared with
nonusers. When we looked at the cause of death, we found that PPI use was particularly
associated with mortality due to cardiovascular diseases and infectious diseases. We also
demonstrated that mortality risk is highest among KTRs taking high PPI dosages (>20
mg omeprazole equivalents/day).
• These findings were replicated in an independent cohort of 656 KTRs from the Univer-
sity Hospitals Leuven, which strengthens the evidence for an association between PPI
use and mortality risk in KTRs.
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TransplantLines study, by mailing to
transplantlines@umcg.nl. Data from the BIOBANK
Renal Transplantation University Hospitals Leuven
can be made available by mailing the ethics
committee of the University Hospitals Leuven
EC@UZLEUVEN.BE. Public sharing of individual
participant data was not included in the informed
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What do these findings mean?
• Results of this study suggest that PPI use is associated with mortality risk in KTRs, inde-
pendent of potential confounders.
• The current study highlights the importance of an evidence-based indication for PPI
treatment and provides a rationale to perform a randomized controlled trial on chronic
PPI therapy in KTRs.
1. Introduction
Renal transplantation is considered the preferred treatment for patients with end-stage renal
disease, providing improved prognosis and quality of life at lower cost compared with dialysis
treatment [1–3]. Although short-term outcomes after renal transplantation have tremendously
improved over the last decades, long-term graft survival and mortality rates have shown little
improvement [4–6]. Indeed, mortality rates in kidney transplant recipients (KTRs) are still 6
times higher than in the general population [7].
In search of modifiable risk factors of this excess mortality, iatrogenic factors should not be
overlooked. In this respect, proton-pump inhibitors (PPIs) have drawn our attention. PPIs are
commonly prescribed to KTRs to prevent dyspeptic symptoms and complications from immu-
nosuppressive agents. Despite the favorable safety profile of these drugs, which are generally
well tolerated, growing concern and evidence about the potential long-term complications of
PPI therapy are emerging. Since the first case report of PPI induced hypomagnesemia [8],
numerous observational studies have demonstrated that chronic PPI use is associated with sev-
eral adverse health outcomes, including increased risk of nutrient deficiencies [9–15], Clostrid-
ium difficile infections [16,17], community acquired pneumonia [18], acute and chronic
kidney disease [19–21], and end-stage renal disease [22]. Given that KTRs are prone to nutri-
ent deficiencies, have a high burden of premature cardiovascular morbidity, and recurrent
infections due to use of immunosuppressive medication, KTRs might especially be susceptible
to adverse effects of PPI use.
Recently, several observational studies have demonstrated that PPI use may be associated
with an increased risk of mortality in elderly patients [23–25]. Interestingly, the same prospec-
tive association between PPI use and increased mortality risk was found in a large cohort study
of United States veterans [26] and in a cohort of 1,776 hemodialysis patients [27]. Whether
chronic PPI use is associated with an increased risk of mortality in KTRs is currently
unknown. Therefore, we investigated the effect of PPI therapy on mortality in a large single-
center cohort of stable outpatient KTRs. Because of the observational nature of our data—and
the fact that, for the primary cohort, baseline assessments were performed at varying time after
transplantation, which could have induced survival bias—we investigated whether our find-
ings could be replicated in an independent cohort of stable KTRs, in which baseline assess-
ments have been conducted without variation in time after transplantation [28].
2. Methods
2.1 Design and study population
This is a post hoc analysis using data from a previously described cohort of 707 stable KTRs,
registered as the TransplantLines Food and Nutrition Biobank and Cohort Study
PLOS MEDICINE Proton-pump inhibitors and mortality after kidney transplantation
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1003140 June 15, 2020 3 / 19
(ClinicalTrials.gov Identifier NCT02811835), which is a prospective cohort study intended to
investigate the relationship between dietary acid load, ammoniagenesis, and its potential influ-
ence on blood pressure [29]. In summary, all adult KTRs with a functioning graft for at least 1
year after transplantation who visited the outpatient clinic of the University Medical Center
Groningen (UMCG) between November 2008 and March 2011 were invited to participate in
the study. KTRs were not considered eligible for the study in case of concurrent systemic ill-
nesses, including malignancies other than cured skin cancer, opportunistic infections, and
overt congestive heart failure. Of the initially 817 invited KTRs, 707 (87%) gave written
informed consent. We excluded KTRs with missing data on PPI dosage (n = 1) or with on-
demand PPI use (n = 3), leaving 703 KTRs eligible for the current post hoc analysis. All mea-
surements were performed during a single study visit at the outpatient clinic. The primary
endpoint of this study was all-cause mortality. In response to peer-review comments, we
added cause-specific mortality (i.e., death due to cardiovascular diseases, infectious diseases,
malignant diseases, and miscellaneous causes) and occurrence of graft failure as secondary
endpoints. Follow-up was recorded until September 2015, and upon request of one of the
reviewers, it was extended to December 31, 2018. Continuous surveillance of the outpatient
program ensures up-to-date information on patient status, which was recorded in the UMCG
Renal Transplantation Database and verified with the Dutch Civil Registration Office. Medical
records, general practitioners, and nephrologist were consulted to establish cause of death.
Cardiovascular mortality was defined as death due to cerebrovascular disease, ischemic heart
disease, heart failure, or sudden cardiac death International Classification of Diseases, Ninth
Revision (ICD-9) codes 410–447, infectious disease mortality was defined according to ICD-9
codes 1–139, and cancer mortality was defined according to a specified list of ICD-9 codes
[30]. The study protocol was approved by the institutional review board of the UMCG (IRB
identifier 2008–186). All study procedures were performed in accordance with the Declaration
of Helsinki and the Declaration of Istanbul.
For the replication study, we used data from an independent cohort of stable KTRs from
the University Hospitals Leuven [28]. In summary, in the University Hospitals Leuven Renal
Transplant Program, the majority of patients (>95%) are enrolled in a prospective Renal
Transplant Biobank Program (ClinicalTrials.gov identifier NCT01331668). We used data from
a previously described cohort in which patients were seen at the outpatient clinic at 3, 12, and
24 months after transplantation, and yearly thereafter [28]. During the outpatient clinic visit,
routine laboratory analyses were performed together with a physical examination. Survival
time was defined from the date of the last study visit until date of death or end of follow-up.
KTRs who developed graft failure during follow-up (i.e., return to dialysis or re-transplanta-
tion) were censored at time of graft failure. Information on clinical parameters, including
medication use, weight, and laboratory results, was obtained from electronic clinical patient
charts. All participants provided written informed consent. The study was approved by the
Ethics Committee of the University Hospitals Leuven (S53364; ML7499). This study is
reported as per the Strengthening the Reporting of Observational Studies in Epidemiology
(STROBE) guideline (S1 STROBE Checklist) and Transparent Reporting of a Multivariable
Prediction Model for Individual Prognosis or Diagnosis (TRIPOD) guideline (S1 TRIPOD
Checklist).
2.2 Clinical parameters and measurements
Information on medical history, including primary renal disease, was obtained from patient
records [29]. Transplant-specific characteristics were retrieved from the local University Medi-
cal Center Groningen Renal Transplantation Database. History of cardiovascular disease was
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classified according to International Classification of Diseases, Tenth Revision (ICD-10) codes
Z86.7. KTRs were considered to have diabetes when at least one of the following criteria was
met: (1) symptoms of diabetes (e.g., polyuria, polydipsia, unexplained weight loss) plus casual
plasma glucose concentration of�11.1 mmoL/L (200 mg/dL), (2) fasting plasma glucose con-
centration�7.0 mmol/L (126 mg/dL), (3) use of antidiabetic medication, or (4) plasma hemo-
globin A1c (HbA1c)�6.5% (48 mmol/L). Body mass index (BMI) was calculated as weight in
kilograms divided by height in meters squared. Blood pressure was measured according to a
strict protocol, as previously described in detail [31]. Information on alcohol use and smoking
behavior was obtained using a questionnaire (see S1 Appendix). Medication use, including use
of PPIs, was recorded at baseline and verified with medical records. KTRs using any PPI on a
daily basis during a period of at least 3 months before and 3 months after the study visit were
defined as chronic PPI users.
Blood samples were collected after an 8- to 12-hour overnight fasting period. Serum creati-
nine was measured using an enzymatic, isotope dilution mass spectrometry–traceable assay
(P-Modular automated analyzer, Roche Diagnostics, Basel, Switzerland). Estimated glomerular
filtration rate (eGFR) was calculated applying the serum creatinine–based Chronic Kidney
Disease Epidemiology Collaboration (CKD-EPI) equation [32]. Concentrations of cholesterol,
triglycerides, and HbA1c were determined using standard laboratory methods. All participants
were instructed to collect a 24-hour urine sample according to a strict protocol on the day
prior to their visit to the outpatient clinic. Urine was collected under oil, and chlorhexidine
was added as antiseptic agent. Total urinary protein concentration was determined using the
Biuret reaction (MEGA AU 510, Merck Diagnostica, Darmstadt, Germany). Proteinuria was
defined as urinary protein excretion�0.5 g/24 h.
2.3 Statistical analyses
Statistical analyses were performed with SPSS software, version 23.0 (IBM Corp., Armonk,
NY) and Stata version 14.2 (StataCorp LP, College Station, TX). Data are presented as
mean ± SD for normally distributed data or as median with interquartile range (IQR) for non-
normally distributed data and number with percentage for nominal data. Differences between
PPI users and nonusers were tested using an independent-sample t test for normally distrib-
uted data, Mann-Whitney U test for non-normally distributed data, or chi-squared test for cat-
egorical data.
A Kaplan-Meier curve was used to illustrate the association of PPI use on patient survival,
and significance was tested using the log-rank test. Survival time was defined as the time from
baseline visit until the date of death or end of follow-up (December 31, 2018). KTRs who
developed graft failure during follow-up (i.e., return to dialysis or re-transplantation) were
censored at time of graft failure. Multivariable Cox proportional hazard regression analyses
were performed to analyze whether the hypothesized association of PPI use with mortality was
independent of potential confounders. To adjust for confounders, multiple models were built.
In model 1, we adjusted for age, sex, BMI, and time since transplantation; in model 2, we fur-
ther adjusted for eGFR and proteinuria, deceased donor transplant, preemptive transplanta-
tion, and primary renal disease, cumulative to already existing adjustments performed in
model 1. Because of the limited number of events and the rule of thumb of allowing for one
covariate per approximately 10 events to prevent overfitting and overadjustment of the mod-
els, further models were performed with additive adjustments to model 2 [33,34]. In model 3,
we additionally adjusted for donor characteristics and immunological factors (donor age,
donor sex, donor height, donor weight, donor serum creatinine, number of Human Leukocyte
Antigen [HLA] mismatches, and applied induction therapy). (This model was added in
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response to a comment from one of the reviewers.) In model 4, we adjusted for lifestyle parame-
ters (alcohol use and smoking behavior). In model 5, we adjusted for medication use (antihyper-
tensive drugs, platelet inhibitors, vitamin K antagonists, proliferation inhibitors, and calcineurin
inhibitors [CNIs]), and in model 6, we adjusted for comorbidities (diabetes and history of car-
diovascular disease), in addition to adjustments in model 2. In model 7, we performed adjust-
ment for plasma magnesium and serum iron, in addition to adjustments in model 2, to
investigate whether these variables were potential mediators of the association between PPI use
and mortality. In response to a request from one of the reviewers, we additionally performed
analyses in which we adjusted for all covariates from models 1–6 in a final cumulative model. To
avoid overadjustment bias due to inclusion of overlapping covariates within one biological
domain, we ran 2 analyses. In one analysis we excluded diabetic nephropathy, vitamin K antago-
nists, platelet inhibitors, and use of anti-hypertensive drugs from the final model, and in another
analysis we excluded diabetes and cardiovascular disease history from the final model [35,36].
The proportional hazards assumption was tested using the Schoenfeld global test and was not
violated in any of the models. In response to peer-review comments, we added analyses on
potential effect modification by age, sex, eGFR, diabetes, and medication for which significant
baseline differences were present, including the use of antihypertensive drugs, platelet inhibitors,
vitamin K antagonists, and CNIs. This was tested by adding interaction terms consisting of PPI
use and the variable of interest to model 2 of the Cox regression analyses.
To explore a potential dose-response relationship, we performed additional Cox regression
analyses in which KTRs were divided into 3 groups based on daily PPI dose defined in omep-
razole equivalents: no PPI, low PPI dose (�20 mg omeprazole equivalents/day), and high PPI
dose (>20 mg omeprazole equivalents/day) as described previously [37]. Tests of linear trend
were conducted by assigning the median of daily PPI dose equivalents in subgroups treated as
a continuous variable.
In response to peer-review comments, we performed secondary analyses for the association
of PPI use with cause-specific mortality (i.e., death due to cardiovascular diseases, infectious
diseases, malignant diseases, and miscellaneous causes), death-censored graft failure, and
biopsy proven acute rejection (BPAR). Because of lower numbers of events available for these
endpoints, analyses were limited to the first 2 models. We also investigated whether PPI use
was associated with eGFR decline, because PPI use has been associated with acute interstitial
nephritis in the past. Information on the last measurement of serum creatinine before occur-
rence of either death, death-censored graft failure, or end of follow-up was obtained from
medical records. These levels were used to calculate the eGFR at the moment closest to patient
death. The delta eGFR in mL/min/1.73 m2 was calculated by subtracting the baseline eGFR
from the eGFR at follow-up. Linear regression analyses with delta eGFR as dependent variable
and PPI use as independent variable were performed to investigate the association of PPI use
with change in eGFR. Furthermore, in response to peer-review comments, we performed sen-
sitivity analyses in which we adjusted for eGFR change cumulative to already existing adjust-
ments performed in model 2 of the Cox regression analyses. We performed multiple
imputations (n = 5) to account for missing data on baseline characteristics in our Cox regres-
sion analyses [38]. Results of the imputed dataset were compared with the results of the non-
imputed dataset and showed no relevant differences (S1 Table). In all analyses, a two-sided
P< 0.05 was considered statistically significant.
3. Results
Baseline characteristics of the TransplantLines study are shown in Table 1. Mean age at base-
line was 53 ± 13 years, and 401 (57.0%) KTRs were male. Mean BMI was 26.7 ± 4.8 kg/m2, and
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Table 1. Baseline characteristics of 703 KTRs from the TransplantLines study.
Characteristics Total population Non-PPI users PPI users P
Number of participants , n (%) 703(100) 305 (43.4) 398 (56.6) n/a
Demographics
Age, y 53 ± 13 51 ± 13 54 ± 12 0.001
Men, n (%) 401 (57.0) 179 (58.7) 222 (55.8) 0.4
Height, cm 174 ± 10 174 ± 10 174 ± 10 1.0
BMI, kg/m2 26.7 ± 4.8 26.0 ± 4.6 27.2 ± 4.9 0.001
Diabetes mellitus, n (%) 168 (23.9) 56 (18.4) 112 (28.1) 0.003
Cardiovascular disease history, n (%) 280 (39.8) 95 (31.1) 185 (46.5) <0.001
Lifestyle parameters
Current smoker, n (%)a 84 (12.8) 35 (12.2) 49 (13.3) 0.7
Alcohol consumer, n (%)a 442 (69.8) 199 (72.1) 243 (68.1) 0.3
Primary renal disease
Glomerulonephritis, n (%) 189 (26.9) 89 (29.2) 100 (25.1) 0.2
Interstitial nephritis, n (%) 86 (12.2) 49 (16.1) 37 (9.3) 0.007
Cystic kidney disease, n (%) 145 (20.6) 53 (17.4) 92 (23.1) 0.06
Other congenital and hereditary kidney disease, n (%) 42 (6.0) 24 (7.9) 18 (4.5) 0.06
Renal vascular disease, n (%) 38 (5.4) 19 (6.2) 19 (4.8) 0.4
Diabetes Mellitus, n (%) 36 (5.1) 8 (2.6) 28 (7.0) 0.009
Other multisystem diseases, n (%) 49 (7.0) 17 (5.6) 32 (8.0) 0.2
Other, n (%) 16 (2.3) 7 (2.3) 9 (2.3) 1.0
Unknown, n (%) 102 (14.5) 39 (12.8) 63 (15.8) 0.3
Transplantation characteristics
Time since transplantation, y 5.4 [1.9-12.0] 9.4 [4.1-15.0] 4.1 [1.2-8.5] <0.001
Pre-emptive transplantation, n (%) 113 (16.1) 45 (14.8) 68 (17.1) 0.4
Total HLA mismatches a 2 [1 – 3] 2 [1 – 3] 2 [1 – 3] 0.04
Induction therapy b <0.001
Anti-thymocyte globulin 61 (9.1) 20 (7.1) 41 (10.6)
CD3 receptor MoAb 16 (2.4) 11 (3.9) 5 (1.3)
IL2 receptor MoAb 348 (52.0) 106 (37.7) 242 (62.4)
Other 29 (4.3) 15 (5.3) 14 (3.6)
None 215 (32.1) 129 (45.9) 86 (22.2)
Donor characteristics
Deceased donor, n (%) 462 (65.9) 212 (69.7) 250 (63.0) 0.06
Men, n (%)b 355 (51.7) 156 (53.2) 199 (50.5) 0.5
Age, y b 42 ± 15 40 ± 16 45 ± 14 <0.001
Weight, kg c 75.8 ± 15.4 74.8 ± 13.3 76.6 ± 16.6 0.2
Height, cm c 174 ± 11 175 ± 9 174 ± 12 0.7
Creatinine, µmol/L c 75 [62 – 93] 75 [62 – 93] 80 [63 – 92] 0.9
Renal function parameters
eGFR, ml/min/1.73 m2 52.2 ± 20.1 54.8 ± 19.9 50.1 ± 20.0 0.002
Serum creatinine, µmol/L 125 [100-161] 119 [99-153] 128 [101-168] 0.04
Proteinuria (�0.5 g/24h), n (%) 158 (22.5) 71 (23.3) 87 (22.0) 0.7
Hemodynamic parameters
Systolic blood pressure, mmHg 136 ± 18 133 ± 17 138 ±18 <0.001
Diastolic blood pressure, mmHg 83 ± 11 82 ± 11 83 ± 11 0.4
Heart rate, bpmc 69 ± 12 67 ± 12 70 ± 12 0.02
Laboratory parameters
(Continued)
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168 (23.9%) KTRs met the criteria for diabetes. KTRs were included in the study at a median
of 5.4 (1.9–12.0) years post transplantation, and 462 (65.9%) KTRs received a kidney trans-
plant from a deceased donor. Mean eGFR was 52.2 ± 20.1 ml/min/1.73 m2, and 158 (22.5%)
KTRs had proteinuria. A small majority of 398 (56.6%) KTRs used PPIs. The most commonly
used PPI was omeprazole (n = 347) accounting for 87% of all PPIs used, followed by esomepra-
zole (n = 31), pantoprazole (n = 17), and rabeprazole (n = 3). At baseline, we observed that PPI
users were significantly older compared with nonusers, had a higher BMI, and were included
with a shorter time interval between transplantation and baseline measurements. Furthermore,
diabetes was more common among PPI users, and KTRs who used PPIs had higher systolic
blood pressure, heart rate, and HbA1c levels and lower levels of high-density lipoprotein
(HDL) cholesterol. Additionally, treatment with other medications, including antihypertensive
dugs, platelet inhibitors, vitamin K antagonists, and CNIs, was more prevalent among PPI
users compared with nonusers (Table 1). Of the KTRs using platelet inhibitors, 1 PPI nonuser
(0.3%) versus 6 PPI users (1.5%) were on dual antiplatelet medication (P = 0.2).
3.1 PPI use and mortality risk
Median follow-up of the TransplantLines study was 8.2 years. During this period, 110 KTRs
developed graft failure and were censored at time of graft failure, and 194 (27.6%) KTRs died
with a functioning graft. The majority of KTRs died due to cardiovascular disease (37.1%), fol-
lowed by death due to infectious diseases (24.2%), miscellaneous causes (20.1%), and
Table 1. (Continued)
Characteristics Total population Non-PPI users PPI users P
Magnesium, mmol/L 0.77 ± 0.11 0.79 ± 0.09 0.76 ± 0.12 <0.001
Iron, µmol/L 15.3 ± 6.0 16.4 ± 6.1 14.4 ± 5.8 <0.001
Total cholesterol, mmol/L 5.1 ± 1.1 5.2 ± 1.1 5.1 ± 1.2 0.5
HDL-cholesterol, mmol/Lb 1.3 [1.1-1.6] 1.4 [1.1-1.7] 1.3 [1.0-1.6] <0.001
LDL-cholesterol, mmol/Lb 3.0 ± 0.9 3.0 ± 1.0 2.9 ± 0.9 0.2
Triglycerides, mmol/L 1.7 [1.3-2.3] 1.6 [1.1-2.1] 1.7 [1.3-2.5] 0.002
Glucose, mmol/L 5.3 [4.8-6.0] 5.2 [4.7-5.8] 5.3 [4.8-6.2] 0.02
HbA1c, %b 5.8 [5.5-6.2] 5.7 [5.4-6.0] 5.9 [5.6-6.3] <0.001
Medication use
Antihypertensive drugs, n (%) 620 (88.2) 252 (82.6) 368 (92.5) <0.001
Platelet inhibitors, n (%) 144 (20.5) 48 (15.7) 96 (24.1) 0.006
Dual antiplatelet therapy, n (%) 7 (1) 1 (0.3) 6 (1.5) 0.2
Vitamin K antagonists, n (%) 77 (11.0) 21 (6.9) 56 (14.1) 0.003
Statins, n (%) 371 (52.8) 148 (48.5) 223 (56.0) 0.05
Proliferation inhibitors, n (%) 583 (82.9) 251 (82.3) 332 (83.4) 0.7
CNIs, n (%) 406 (57.8) 150 (49.2) 256 (64.3) <0.001
Prednisolone, n (%) 696 (99.0) 303 (99.3) 393 (98.7) 0.7




Abbreviations: BMI, body mass index; CD3 MoAb; CD3 monoclonal antibody; CNI, calcineurin inhibitor; eGFR, estimated glomerular filtration rate; HbA1c,
hemoglobin A1c; HDL, high-density lipoprotein; HLA, Human Leukocyte Antigen; IL2 MoAb, interleukin-2 receptor monoclonal antibody; IQR, interquartile range;
KTR, kidney transplant recipient; LDL, low-density lipoprotein; n/a, not applicable; PPI, proton-pump inhibitor
https://doi.org/10.1371/journal.pmed.1003140.t001
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malignant diseases (18.6%). Out of the 398 KTRs who used PPIs at baseline, 132 (33.2%) died
during follow-up, whereas out of the 305 KTRs who did not use PPIs at baseline, 62 (20.3%)
died during follow-up (log-rank test P< 0.001, Fig 1). Cox regression analysis revealed that
PPI users had an increased risk of mortality compared with nonusers (hazard ratio [HR] 1.86,
95% CI 1.38–2.52, P< 0.001, Table 2). Adjustment for potential confounders—including age,
sex, BMI, eGFR, proteinuria, time since transplantation, preemptive transplantation, deceased
donor transplant, and primary renal disease—did not substantially affect the association (HR
1.68, 95% CI 1.21–2.33, P = 0.002, Table 2). Additionally, the association remained indepen-
dent of adjustment for other potential confounding factors, including donor characteristics,
immunological factors, lifestyle parameters, medication use, and comorbidities. Adjustment
for plasma magnesium and serum iron as potential mediators of the association between PPI
use and mortality did not materially alter the association (HR 1.53, 95% CI 1.09–2.14, P = 0.01,
Table 2). In a final model in which we adjusted for all variables of models 1–6 combined
(except diabetic nephropathy, vitamin K antagonists, platelet inhibitors, and use of antihyper-
tensive drugs), the association between PPI use and all-cause mortality remained (HR 1.42,
95% CI 1.01–2.00, P = 0.04). Alternatively, the association between PPI use and all-cause mor-
tality remained in a final model in which we adjusted for all variables of models 1–6 combined
except diabetes and cardiovascular disease history (HR 1.46, 95% CI 1.03–2.05, P = 0.03). No
significant interactions were found between PPI use and age, sex, eGFR, diabetes, and medica-
tion for which significant baseline differences were present—including antihypertensive
drugs, platelet inhibitors, vitamin K antagonists, and CNIs (Pinteraction > 0.05).
Fig 1. Kaplan-Meier survival curve for all-cause mortality of PPI users compared with nonusers from the
TransplantLines study. PPI, proton-pump inhibitor.
https://doi.org/10.1371/journal.pmed.1003140.g001
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Cause-specific analyses revealed that PPI use was particularly associated with an increased
risk of cardiovascular mortality (HR 2.42, 95% CI 1.43–4.08, P< 0.001). This association
remained significant after adjustment for potential confounding factors (S2 Table). Moreover,
we found an increased mortality risk due to infectious diseases among PPI users (HR 1.89,
95% CI 1.02–3.49, P = 0.04), although the association was slightly attenuated after adjustment
for potential confounders (HR 1.88, 95% CI 0.96–3.71, P = 0.07, S2 Table). We did not observe
a significant association between PPI use and death due to malignant diseases or miscellaneous
causes (S2 Table). Furthermore, we found that PPI use was not significantly associated with a
higher risk of graft failure (HR 1.20, 95% CI 0.82–1.75, P = 0.4, S3 Table). Only 13 KTRs devel-
oped BPAR during follow-up. We found no significant association between PPI use and subse-
quent development of BPAR (HR 1.73, 95% CI 0.53–5.61, P = 0.4). Unfortunately, the low
number of events does not allow for meaningful analyses with adjustment for potential con-
founders of this association.
Median time between baseline eGFR and eGFR at follow-up was 6.5 (4.6–8.6) years. Mean
change in renal function over this period was −7.13 ± 17.1 ml/min/1.73 m2. In crude linear
regression analysis, PPI use was not associated with eGFR decline (β = 0.75, 95% CI −1.82 to
3.32, P = 0.6, S4 Table). Additional adjustment for time from baseline to follow-up, age, sex,
and BMI did not substantially alter the association (β = 0.10, 95% CI −2.45 to 2.66, P = 0.9, S4
Table). Results from Cox regression analyses for the association of PPI use with all-cause mor-
tality analogous to model 2 remained materially unchanged when we adjusted for change in
eGFR (HR 1.68, 95% CI 1.22–2.33, P = 0.002).
Dose response analysis
We also investigated whether KTRs taking a high PPI dose (>20 mg omeprazole equivalents/
day) were at a higher risk for premature mortality compared with KTRs on a low PPI dose
(�20 mg omeprazole equivalents/day). At baseline, 257 KTRs used a low PPI dose, and 141
Table 2. Association of PPI use with mortality in 703 stable KTRs from the TransplantLines study.
All-Cause Mortality
Number of events = 194 HR 95% CI P
Crude 1.86 1.38–2.52 <0.001
Model 1 1.73 1.25–2.38 0.001
Model 2 1.68 1.21–2.33 0.002
Model 3 1.67 1.19–2.34 0.003
Model 4 1.63 1.17–2.27 0.007
Model 5 1.49 1.07–2.09 0.02
Model 6 1.46 1.04–2.03 0.03
Model 7 1.53 1.09–2.14 0.01
Model 1: PPI use adjusted for age, sex, BMI, and time since transplantation. Model 2: Model 1 additionally adjusted
for eGFR, proteinuria, deceased donor transplant, preemptive transplantation, and primary renal disease. Model 3:
Model 2 additionally adjusted for donor age, donor sex, donor weight, donor height, donor serum creatinine,
number of HLA mismatches, and induction therapy. Model 4: Model 2 additionally adjusted for smoking behavior
and alcohol use. Model 5: Model 2 additionally adjusted for the use of antihypertensive agents, platelet inhibitors,
vitamin K antagonists, proliferation inhibitors, and CNIs. Model 6: Model 2 additionally adjusted for comorbidities
(diabetes, history of cardiovascular disease). Model 7: Model 2 additionally adjusted for potential mediators (plasma
magnesium and serum iron).
Abbreviations: BMI, body mass index; CNI, calcineurin inhibitor; eGFR, estimated glomerular filtration rate; HLA,
Human Leukocyte Antigen; HR, hazard ratio; KTR, kidney transplant recipient; PPI, proton-pump inhibitor
https://doi.org/10.1371/journal.pmed.1003140.t002
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KTRs used a high PPI dose. The association between PPI use and mortality risk appeared to be
dose dependent, with the higest risk for premature mortality found among KTRs taking more
than 20 mg omeprazole equivalents/day (Ptrend < 0.001, Table 3).
3.2 Results replication study
Baseline characteristics from the Leuven Renal Transplant Cohort are shown in S5 Table. PPIs
were used by 329 KTRs (50.2%). In this cohort, PPI users were significantly older (57 ± 12
years versus 54 ± 13 years, P = 0.001) and had higher triglyceride levels and HbA1c levels.
More PPI users had a history of cardiovascular disease compared with nonusers (27.4% versus
19.0%, P = 0.01). Additionally, use of platelet inhibitors and prednisolone was more common
among PPI users compared with nonusers.
Median follow-up of the Leuven Renal Transplant Cohort was 3.7 years. During this period,
97 (17.2%) KTRs died with a functioning graft. Out of the 329 KTRs who used PPIs at baseline,
65 (19.8%) died during follow-up, whereas out of the 327 KTRs who did not use PPIs at base-
line, 32 (9.8%) died during follow-up (log-rank test P< 0.001, Fig 2). Prospective analysis
showed that PPI users had a more than 2 times higher risk of mortality compared with nonus-
ers (HR 2.47, 95% CI 1.61–3.78, P< 0.001, crude model, S6 Table). Further adjustment for
potential confounders, including age, sex, time since transplantation, preemptive transplanta-
tion, deceased donor transplant, and primary renal disease, did not substantially affect this
association (HR 1.75, 95% CI 1.12–2.73, P = 0.01). These results were similar to results
obtained in the TransplantLines study.
4. Discussion
This study shows that PPI use is associated with an increased mortality risk in 2 large indepen-
dent cohort studies of stable KTRs. Although significant baseline differences between PPI
Table 3. Subgroup analyses of the association of PPI use with mortality in 703 stable KTRs from the TransplantLines study.
All-Cause Mortality
No PPI Low PPI dose High PPI dose
Number of participants/events 305/62 257/80 141/52
HR (95% CI) P HR (95% CI) P HR (95% CI) P Ptrend
Crude Reference n/a 1.72 (1.23–2.39) 0.001 2.14 (1.48–3.09) <0.001 <0.001
Model 1 Reference n/a 1.57 (1.10–2.23) 0.01 2.03 (1.38–2.97) <0.001 <0.001
Model 2 Reference n/a 1.57 (1.08–2.24) 0.02 1.88 (1.27–2.77) 0.002 0.001
Model 3 Reference n/a 1.53 (1.05–2.22) 0.03 1.90 (1.28–2.83) 0.002 0.001
Model 4 Reference n/a 1.52 (1.06–2.19) 0.05 1.81 (1.22–2.48) 0.003 0.002
Model 5 Reference n/a 1.41 (0.97–2.04) 0.07 1.62 (1.09–2.42) 0.02 0.02
Model 6 Reference n/a 1.39 (0.97–1.99) 0.1 1.57 (1.06–2.32) 0.03 0.02
Model 7 Reference n/a 1.47 (1.02–2.12) 0.04 1.62 (1.09–2.44) 0.02 0.02
Model 1: PPI use adjusted for age, sex, BMI, and time since transplantation. Model 2: Model 1 additionally adjusted for eGFR, proteinuria, deceased donor transplant,
preemptive transplantation, and primary renal disease. Model 3: Model 2 additionally adjusted for donor age, donor sex, donor weight, donor height, donor serum
creatinine, number of HLA mismatches, and induction therapy. Model 4: Model 2 additionally adjusted for smoking behavior and alcohol use. Model 5: Model 2
additionally adjusted for the use of antihypertensive agents, platelet inhibitors, vitamin K antagonists, proliferation inhibitors, and CNIs. Model 6: Model 2 additionally
adjusted for comorbidities (diabetes, history of cardiovascular disease). Model 7: Model 2 additionally adjusted for potential mediators (plasma magnesium and serum
iron).
Abbreviations: BMI, body mass index; eGFR, estimated glomerular filtration rate; HLA, Human Leukocyte Antigen; HR, hazard ratio; KTR, kidney transplant
recipient; n/a, not applicable; PPI, proton-pump inhibitor
https://doi.org/10.1371/journal.pmed.1003140.t003
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users and KTRs who did not use PPIs were present, the association remained materially
unchanged after adjustment for potential confounders. Moreover, we observed that the HR for
mortality risk in KTRs taking a high PPI dose was higher than in KTRs taking a low PPI dose.
Results from survival analysis in the Leuven Renal Transplant Cohort were similar to results
obtained in the TransplantLines study.
Our main observation of an independent association between PPI use and increased mor-
tality risk in KTR is in accordance with previous findings of a large (n = 349,312) longitudinal
observational cohort study among United States veterans. This study found an increased mor-
tality risk among PPI users, compared with users of H2-receptor antagonists and participants
who used neither PPIs nor H2-receptor antagonists [26]. Several small cohort studies among
institutionalized elderly and older patients recently discharged from emergeny departments
also demonstrated that PPI use is associated with an increased risk of mortality [23–25]. In
addition, PPI use was found to be an independent predictor of mortality in 1,776 hemodialysis
patients (HR 2.70, 95% CI 1.38–5.27, P< 0.01) [27]. In our study, the increased risk of prema-
ture mortality associated with PPI use was higher than previously reported by Xie and col-
leagues [26]. Apparently, the increase in risk arising from inhibition of gastric acid secretion is
higher in KTRs than in the general population. It is conceivable that in light of active immuno-
suppression and an existing high burden of atherosclerosis, PPIs might increase susceptibility
to serious infections and/or accelerate atherosclerosis, leading to more pronounced shortening
of life expectancy.
Several physiological mechanisms may underlie the observed association between PPI use
and mortality. It has been widely documented that PPIs may affect absorption of micronutri-
ents, leading to deficiencies of important electrolytes, including iron and magnesium
Fig 2. Kaplan-Meier survival curve for all-cause mortality of PPI users compared with nonusers from the Leuven
Renal Transplant Cohort. PPI, proton-pump inhibitor.
https://doi.org/10.1371/journal.pmed.1003140.g002
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[11,14,15]. Indeed, we previously found that PPI use was associated with iron deficiency and
hypomagnesemia in KTRs [37,39]. Iron deficiency can in turn lead to iron deficiency anemia,
which has been linked to a higher graft failure risk and mortality risk in KTRs [40–42]. Fur-
thermore, low serum magnesium and urinary magnesium excretion are known risk factors for
the development of hypertension, cardiovascular disease, and mortality in the general popula-
tion [43–45], and low serum magnesium levels have been linked to mortality in patients with
early stages of chronic kidney disease [46]. Additionally, PPI use has been associated with
increased risk of cardiovascular mortality in the general population, which we also observed in
our study [47]. It could be speculated that the higher mortality risk observed is attributable to
lower iron and magnesium status in PPI users. However, when we adjusted for iron and mag-
nesium levels in prospective analyses, the relationship between PPI use and mortality
remained unaltered, implying that the observed risk associated with PPI use could not be
attributed to lower iron and magnesium status and that other mechanisms are likely involved.
Another explanation might be that other adverse effects related to PPI use, such as an
increased risk of gastrointestinal infections, community-acquired pneumonia, and acute and
chronic kidney disease, collectively carry an increased mortality risk [18–20,48,49]. Unfortu-
nately, data on gastrointestinal infections and community-acquired pneumonia were unavail-
able in our study. Therefore, we were unable to investigate this hypothesis.
A relatively unexplored field in nephrology is the gut microbiome and its role in develop-
ment of disease and adverse health outcome after renal transplantation. It has previously been
shown that PPIs have the ability to drastically change the composition of gut microbiota result-
ing in a less healthy gut microbiota with a lower diversity and a tendency towards C. difficile
and other enteric infections [50,51]. Moreover, gut microbial dysbiosis has been linked to
post-transplantation complications such as rejection and graft versus host disease in allogeneic
transplantation [52–54], demonstrating how important the gut microbiome might be in rela-
tion to adverse outcome after transplantation. Furthermore, Evenepoel and colleagues previ-
ously demonstrated that PPIs impair protein digestion, which results in higher protein
availability in the colon and consequently in higher systemic levels of potential nephrotoxic
microbial fermentation products such as p-cresol [55]. However, future research is essential to
elucidate the interplay between PPI use, alterations in the gut microbiome, and mortality after
renal transplantation.
Further prospective analysis showed that PPI use was not associated with a higher risk of
graft failure. These findings are consistent with findings from Knorr and colleagues, who did
not find an association between PPI use and graft failure in a cohort of 597 KTRs [56]. In the
present study, a majority of patients (56.6%) used PPIs, indicating the frequent use of PPIs
among KTRs. Chronic use of PPIs has tremendously increased over the past decade, and stud-
ies estimate that in both primary and hospital care 30% to 65% of patients that chronically use
PPIs are using it for an inappropriate indication [57–61], including, e.g., corticosteroid therapy
without concomitant nonsteroidal anti-inflammatory drug (NSAID) use [61,62]. Inappropri-
ate use of PPIs may be frequent in KTRs, since PPIs are commonly prescribed to prevent gas-
trointestinal complaints and complications of immunosuppressive medication, particularly of
corticosteroid therapy [63]. According to the Food and Drug Administration (FDA) guide-
lines, PPI use is not routinely indicated in this situation [64,65].
Our results might have important implications for clinical practice. The present study high-
lights the importance of an evidence-based indication for PPI treatment and suggests that
treatment indication may need to be revisited in KTRs. Hence, physicans should deliberate
whether the benefits of PPI therapy outweigh the risks for each individual patient. Moreover,
rebound acid hypersecretion, a phenomenon that can occur after PPI cessation, might compli-
cate treatment discontinuation [66,67]. It is therefore important that physicians are aware of
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this phenomenon and inform patients about this potential rebound effect while withdrawing
PPI treatment.
One of the strenghts of this study is the use of a prospectively followed cohort of well-char-
acterized KTRs, in which endpoint evaluation was complete with no loss to follow-up. The fact
that we used data from a cohort with extensivley phenotyped participants enabled us to correct
for many possible confounding factors, including lifestyle factors, medication use, and comor-
bidities. Moreover, independent replication in the Leuven Renal Transplant Cohort showed
similar results, which strengthens the evidence for an association between PPI use and mortal-
ity risk in KTR.
However, some limitations need to be taken into consideration. First, the fact that partici-
pants were predominantly Western European Caucasian limits the generalizability of the
results to other populations. In addition, results may not be generalizable to KTRs with oppor-
tunistic infections and patients with overt heart failure given that these patients were not
included in the study. Second, due to the observational design of both studies, a cause-effect
relationship cannot be established with certainty, and despite adjustment for various potential
confounders, the possibility of residual confounding due to unknown or unmeasured variables
remains. On average, PPI users had more risk factors for mortality than nonusers, with the
result that the contribution of PPIs may have been overestimated. Further prospective investi-
gation is needed to validate whether chronic PPI use leads to increased mortality in KTRs or
whether KTRs with increased mortality risk are subjected to more frequent treatment with
PPIs. Furthermore, PPI users were included more shortly after transplantation, which may
have resulted in a survival selection bias. However, prospective analyses with data from the
replication cohort showed similar results. In this cohort, time after transplantation was not sig-
nificantly different between PPI users and nonusers. In addition, data on donor-specific anti-
gens were not available in our cohort, and we could therefore not adjust for this potential
confounder. Lastly, indications for PPI use such as peptic ulcer disease and gastroesophageal
reflux disease may increase risk of death due to malignant diseases. Although confounding by
indication becomes less likely with results of cause-specific analyses, which did not demon-
strate an increased mortality risk from malignant diseases, it cannot be excluded.
In conclusion, we demonstrated that PPI use is associated with an increased risk of all-
cause mortality, with the highest risk among PPI users exposed to a high PPI dose. Further
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Eisenga, Elisabet Van Loon, Joëlle C. Schutten, Rijk O. B. Gans, Maarten Naesens, Else van
den Berg, Ben Sprangers, Stefan P. Berger, Gerjan Navis, Hans Blokzijl, Björn Meijers, Ste-
phan J. L. Bakker, Dirk Kuypers.
References
1. Wolfe RA, Ashby VB, Milford EL, Ojo AO, Ettenger RE, Agodoa LY, et al. Comparison of mortality in all
patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric
transplant. N Engl J Med. 1999 Dec; 341(23):1725–30. https://doi.org/10.1056/
NEJM199912023412303 PMID: 10580071
2. Jofre R, Lopez-Gomez JM, Moreno F, Sanz-Guajardo D, Valderrabano F. Changes in quality of life
after renal transplantation. Am J Kidney Dis. 1998 Jul; 32(1):93–100. https://doi.org/10.1053/ajkd.1998.
v32.pm9669429 PMID: 9669429
3. Schippers HM, Kalff MW. Cost comparison haemodialysis and renal transplantation. Tissue Antigens.
1976 Feb; 7(2):86–90. https://doi.org/10.1111/j.1399-0039.1976.tb01036.x PMID: 775684
4. Lamb KE, Lodhi S, Meier-Kriesche HU. Long-term renal allograft survival in the United States: a critical
reappraisal. Am J Transplant. 2011; 11(3):450–62. https://doi.org/10.1111/j.1600-6143.2010.03283.x
PMID: 20973913
5. Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B. Lack of improvement in renal allograft survival
despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant. 2004; 4
(3):378–83. https://doi.org/10.1111/j.1600-6143.2004.00332.x PMID: 14961990
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